COMPANY PROFILE

Heparegenix

Explore full profile

Preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases

Tübingen, GermanyFounded 2015Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Heparegenix

HepaRegeniX is a biotechnology company focused on discovering and developing innovative drug candidates to treat multiple liver diseases. The company's primary market includes healthcare providers, pharmaceutical companies, and research institutions. HepaRegeniX operates in the biotechnology and pharmaceutical sectors, targeting unmet medical needs in liver disease treatment. The business model revolves around the research and development of proprietary drug candidates, which are then advanced through clinical trials. Revenue is generated through funding rounds, partnerships, and potential future licensing deals or sales of developed drugs. Recently, HepaRegeniX raised a Series C funding round to further the clinical development of its lead candidate, HRX 215, aimed at liver regeneration.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Tübingen, Germany
Employees: 15
Open positions: None listed
Dealroom signal: 58.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Recovery, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jun 2025	$0	—	Wellington Partners · Novo Holdings · Vesalius Biocapital Partners	—
LATE VCOther financing	Apr 2025	$24M	$95M	Wellington Partners	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Heparegenix website traffic

Latest recorded traffic for Heparegenix is 400 monthly website visits, up 400% over the last three months. Heparegenix's team grew 0% over the past year.

Latest monthly visits400 3-month web change+400% 1-year team growth0%

Monthly website visitsJan 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CUCuroTisDevelops implantable regenerative grafts that stimulate the body to grow functional vascular tissue for patients requiring vascular access, such as those undergoing dialysis	Maastricht, Netherlands	Operational	6	—	$14M
AUAutodisplayAutodisplay Technology is Autodisplay Biotech’s first generation cell surface display technology	Düsseldorf, Germany	Operational
TTTenaya TherapeuticsDedicated to discovering and developing novel therapies for heart failures	San Francisco, United States	Operational
MAMabimmuneMabimmune prevents heart attacks through early diagnosis and targeted treatment	Zurich, Switzerland	Operational
ITInCarda TherapeuticsA clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route	Palo Alto, United States	Operational
FOFollicumDeveloping peptide pharmaceuticals with focus on hair regulation and diabetes	Lund Municipality, Sweden	Operational
TOto-BBB.comCombines existing drugs with it's proprietary for enhanced drug delivery across the blood-brain barrier	Leiden, Netherlands	Operational
TTThelial TechnologiesDedicated to improving the treatment of diseases where biological barrier defects are a primary cause	Lisbon, Portugal	Closed